Neomycin Sulphate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Skin Infection, Eye Infection, Ear Infection, Vaccine Production, Veterinary Medicine, Others), By Region and Competition, 2020-2030F

Market Overview

Global Neomycin Sulphate Market was valued at USD 246.80 Million in 2024 and is expected to reach USD 382.05 Million by 2030 with a CAGR of 5.22% during the forecast period. Neomycin sulphate, an aminoglycoside antibiotic, is widely used for the treatment of bacterial infections in both humans and animals due to its broad-spectrum antimicrobial properties. The increasing demand for effective antibacterial agents and the growing focus on preventive healthcare are key factors supporting the expansion of this market.

A primary driver of market growth is the rising prevalence of bacterial infections and gastrointestinal disorders, particularly in developing regions with limited access to clean water and sanitation. Neomycin sulphate is commonly used in topical creams, ointments, and oral preparations to combat bacterial skin infections and prepare the bowel for surgery. Its efficacy in treating a range of infections and its cost-effectiveness make it a valuable therapeutic agent, especially in lower-income countries.

The market faces notable challenges, including stringent regulatory scrutiny and growing awareness of antibiotic resistance. Regulatory authorities in various regions are imposing tighter controls on the use of antibiotics, both in human medicine and animal husbandry, which may limit market growth in the long term. In addition, the availability of alternative antibiotics with improved safety profiles and fewer side effects presents competitive pressure.

Key Market Drivers

Growth in Healthcare Industry

The accelerating growth of the global healthcare industry is emerging as a pivotal driver of the neomycin sulphate market. The global healthcare industry generates annual sales exceeding USD 4 trillion. Among its most significant and profitable segments are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, and medical technology and diagnostics, which account for over USD 400 billion in revenue. Neomycin sulphate, a broad-spectrum aminoglycoside antibiotic, is widely used in pharmaceutical formulations to treat bacterial infections, particularly those affecting the skin, eyes, and intestines. As healthcare systems expand and evolve to meet the rising burden of infectious diseases and the increasing demand for high-quality medical care, the demand for neomycin sulphate continues to rise accordingly.

One of the primary factors fueling this growth is the increasing incidence of bacterial infections worldwide, especially in emerging economies where access to clean water and sanitation remains limited. Hospitals and clinics rely heavily on effective antimicrobial agents like neomycin sulphate to manage superficial infections and prevent complications in both outpatient and surgical settings. Neomycin demonstrates strong localized efficacy against both Gram-negative and Gram-positive bacteria. However, due to its hepatotoxic and ototoxic effects, systemic administration is not recommended. In a treatment series conducted by Kile, certain patients with infections caused by hemolytic Streptococcus and B. pyocyaneus (Pseudomonas aeruginosa) exhibited an unsatisfactory response to neomycin ointment. With the rise in hospital admissions and surgical procedures, the use of topical antibiotics has grown significantly, reinforcing the demand for neomycin-based treatments.

Surge in Technological Advancements

The global neomycin sulphate market is witnessing notable growth, largely fueled by a surge in technological advancements across pharmaceutical manufacturing, biotechnology, and healthcare infrastructure. In 2022, the Steam Explosion and Aerobic Composting (SEA-CBS) system was introduced as an advanced solution for the complete conversion of neomycin fermentation residues into organic fertilizer. The system demonstrated a remarkable antibiotic removal efficiency of up to 99.9% across various categories, including macrolides (kitasamycin and spiramycin), lincosamides (lincomycin), and beta-lactams (cephalosporins and penicillin). Complementary pot experiments were conducted to examine the degradation patterns of residual antibiotics in soil and to assess the distribution of antibiotic resistance genes resulting from trace antibiotic presence.

As a broad-spectrum aminoglycoside antibiotic widely used to treat bacterial infections and prepare the gastrointestinal tract before surgeries, neomycin sulphate continues to benefit from innovation in drug formulation, delivery systems, and production processes. One of the key factors driving this trend is the adoption of advanced biotechnological methods for more efficient and high-yield fermentation processes. Modern bioprocessing techniques allow manufacturers to optimize neomycin production with improved purity levels, shorter production cycles, and reduced operational costs. This technological refinement is especially crucial as pharmaceutical companies strive to meet rising global demand while adhering to stringent quality and safety standards.

Download Free Sample Report

Key Market Challenges

Adverse Side Effects

One of the critical challenges confronting the global neomycin sulphate market is the risk of adverse side effects associated with its usage, particularly in long-term or high-dose treatments. Neomycin sulphate, while effective as a broad-spectrum antibiotic, is known to cause serious side effects such as nephrotoxicity and ototoxicity, which can lead to kidney damage and hearing loss respectively.

These risks have raised concerns among healthcare professionals and regulatory authorities, prompting stricter guidelines on its prescription and usage. In human medicine, its use has become increasingly limited to topical applications or short-term treatments, while alternative antibiotics with more favorable safety profiles are gaining preference. The veterinary sector is also witnessing growing scrutiny due to the potential for drug residues in animal products and the implications for public health.

Key Market Trends

Rising Demand of Neomycin Sulphate in Veterinary Sectors

The rising demand for neomycin sulphate in the veterinary sector has emerged as a significant trend shaping the global neomycin sulphate market. Among poultry species, chickens constitute the dominant segment of global poultry production, accounting for over 90% of the sector, according to industry estimates. Other notable species include ducks, primarily in Asia; turkeys, which are widely bred in North America; guineafowl in Africa; and geese, which also hold a significant position in poultry farming after chickens. As the livestock and poultry industries continue to expand to meet the growing global demand for animal protein, the need for effective veterinary antibiotics particularly for the prevention and treatment of gastrointestinal and topical bacterial infections has intensified. Neomycin sulphate, known for its efficacy against a broad range of gram-negative bacteria, is increasingly being utilized in animal healthcare, driving consistent growth within this segment.

One of the key contributors to this trend is the increasing incidence of bacterial infections in livestock and poultry, which can lead to substantial economic losses if not properly managed. Veterinary formulations containing neomycin sulphate are widely used to treat enteric infections in cattle, pigs, and poultry, particularly during the early stages of growth when animals are more vulnerable. This usage is essential for maintaining animal health, improving feed efficiency, and enhancing overall productivity in the agricultural sector.

Segmental Insights

Sales Channel Insights

Based on Sales Channel, Direct have emerged as the fastest growing segment in the Global Neomycin Sulphate Market in 2024. A primary factor behind this growth is the rising prevalence of bacterial infections, particularly in developing regions with expanding access to healthcare. The increasing incidence of gastrointestinal and skin infections has led to higher consumption of over-the-counter and prescription medications containing neomycin sulphate in its formulated, ready-to-use state. This surge in usage aligns with public health initiatives aimed at improving infection control and reducing antibiotic resistance through prompt treatment.

End Use Insights

Based on End Use, Eye Infection have emerged as the fastest growing segment in the Global Neomycin Sulphate Market during the forecast period. The growing adoption of contact lenses, along with a rise in refractive and cataract surgeries, has increased the risk of post-operative or contact lens–related infections. As a result, there is heightened demand for antibiotic eye drops and ointments containing Neomycin Sulphate as part of pre- or post-operative care. Neomycin Sulphate is known for its affordability and accessibility, especially in developing and emerging markets where cost-effective healthcare solutions are prioritized. Its inclusion in combination ophthalmic formulations (e.g., with dexamethasone or polymyxin B) enhances its value proposition by providing broad-spectrum antimicrobial coverage.

Download Free Sample Report

Regional Insights

Based on Region, Asia Pacific have emerged as the dominating region in the Global Neomycin Sulphate Market in 2024. Countries such as China and India serve as major manufacturing hubs for pharmaceutical ingredients, including neomycin sulphate. These countries benefit from an abundant supply of raw materials, skilled labor, and established chemical processing infrastructure, enabling them to produce neomycin sulphate at significantly lower costs compared to Western markets. This cost advantage enhances their competitiveness in the global supply chain.

Recent Development

• In 2025, Agrovet Market introduced a new range of intramammary suspension antibiotics for the treatment of mastitis in both lactating and dry cows. The product, Pen Tetra Strep LC, combines Penicillin G Procaine, Streptomycin Sulfate, Neomycin Sulfate, and Prednisolone. This formulation, which integrates three antibiotics with complementary mechanisms of action and a powerful glucocorticoid anti-inflammatory agent, provides an effective therapeutic solution for managing mastitis in lactating cows. It offers broad-spectrum antibacterial activity while simultaneously reducing inflammation in mammary tissue.
• In August 2024, the Indian government implemented a major public health initiative by banning 156 fixed-dose combination (FDC) drugs. The list includes formulations such as Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl, along with a range of antibiotics, analgesics, multivitamins, and treatments for fever and hypertension. This regulatory action represents the most extensive crackdown on FDCs since 2016, when 344 such combinations were similarly prohibited.
• In February 2025, BASF India Ltd. broke ground on a new plant in Dahej to expand its Cellasto microcellular polyurethane (MCU) production capacity. While the plant is primarily focused on MCU, it highlights BASF's ongoing commitment to advancing its manufacturing capabilities across various product lines, including active pharmaceutical ingredients like neomycin sulfate. The new facility will feature cutting-edge technology and automation systems to ensure compliance with BASF's rigorous safety and quality standards. Expected to be operational by the second half of 2026, the plant’s first phase will include the installation of a new mold line, positioning BASF to meet growing demand across multiple sectors, including the pharmaceutical industry, where neomycin sulfate is used in various formulations.
• In 2024, Selumetinib was approved as the first treatment for pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN) in the EU, US, and several other countries. The management of selumetinib-related adverse events (AEs) is primarily based on clinical trials and expanded-access programs. Similarly, neomycin sulfate, an aminoglycoside antibiotic, has known adverse effects, such as nephrotoxicity and ototoxicity, managed through clinical research. In both cases, consensus-level agreements have been established for preventing and managing AEs, with Selumetinib achieving consensus on 36 key statements for safety protocols.

Key Market Players

• Pfizer Limited
• Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• Myland Pharma Pvt Ltd
• Xi'an International Healthcare Factory Co., Ltd.
• Shandong Yifan Chemical Technology Co., Ltd.
• Xi'an Henrikang Biotech Co., Ltd.
• Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• Jinyao Xinrui Pharmaceutical
• Xinyu Pharmaceutical
• Renfu Pharmaceutical

Report Scope

In this report, the Global Neomycin Sulphate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Neomycin Sulphate Market, By Sales Channel:

o   Direct

o   Indirect

• Neomycin Sulphate Market, By End Use:

o   Skin Infection

o   Eye Infection

o   Ear Infection

o   Vaccine Production

o   Veterinary Medicine

o   Others

• Neomycin Sulphate Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neomycin Sulphate Market.

Available Customizations:

Global Neomycin Sulphate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Neomycin Sulphate Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]